Should I Buy GRCE? GRCE 2026 Analysis

Should You Buy Grace Therapeutics, Inc (GRCE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

3.600

1 Day change

3.45%

52 Week Range

3.940

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: no proprietary buy signals, weak/uncertain near-term technical setup, and deteriorating quarterly losses.
Options market is pricing extreme uncertainty (very high IV) without strong bullish participation (very low call volume), which is not a clean “buy now” setup.
With no fresh news catalysts and worsening net income/EPS, risk/reward favors avoiding or selling rather than initiating a new position today.

Technical Analysis

Price context: Post-market ~3.675, slightly below the pivot (3.696), indicating a mildly weak immediate bias.
Momentum: MACD histogram is below 0 (-0.0145) and still negative (bearish tilt), though “negatively contracting” suggests downside momentum is not accelerating.
RSI (6): ~51 (neutral), consistent with a range-bound/indecisive tape rather than a strong uptrend entry.
Moving averages: Converging MAs signal consolidation; no clear trend dominance.
Key levels:
- Support: S1 3.51 (then S2 3.394). A break below 3.51 increases downside risk.
- Resistance: R1 3.882 (then R2 3.998). A reclaim above ~3.88 would improve the long setup.
Pattern-based forward view (from similar candlesticks): +0.86% next day (mild), -1.31% next week (soft), +9.18% next month (possible rebound) — but near-term edge is not compelling for “buy immediately.”

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment (open interest): Put/Call OI ratio 0.87 is slightly call-leaning (mildly bullish/less hedged), but not strongly directional.
Volume: Very thin overall (total volume 14; call volume 0 vs put volume 14). Despite the reported volume P/C ratio of 0.0, the tape shows activity concentrated in puts, which is not a bullish confirmation.
Volatility: 30D IV ~691% vs historical vol ~55% with IV percentile ~75 / IV rank ~76.9 — options are extremely expensive, implying the market expects a large move but not clearly in the upside direction.
Activity vs typical: Today’s volume is ~26.9x the 30-day average and open interest is elevated vs average, but absolute liquidity is still small; this can amplify noise rather than signal.

Technical Summary

Sell

Buy

Positive Catalysts

- No news in the past week (reduces surprise downside from fresh negative headlines).
- Consolidation with converging moving averages can set up a breakout if price reclaims and holds above ~3.88 (R1).
- Pattern-projection suggests a possible positive 1-month drift (+9.18%), but it’s not strong enough to override weak fundamentals/signals today.

Neutral/Negative Catalysts

- No Intellectia buy triggers today (AI Stock Picker: none; SwingMax: none), removing the strongest “act now” justification.
- Technicals are not convincingly bullish: price near/below pivot, MACD below zero, and no trend confirmation from moving averages.
- Financial trend deterioration: net loss and EPS worsened meaningfully YoY in the latest quarter.
- Extremely high implied volatility suggests elevated event/price-risk; without a catalyst, the stock can whipsaw rather than trend cleanly.

Financial Performance

Latest quarter: 2026/Q2.
Revenue: 0 (no meaningful top-line), 0.00% YoY.
Profitability: Net income fell to -$938K (down -72.67% YoY), indicating a larger loss.
EPS: -0.06 (down -80.00% YoY), confirming worsening per-share performance.
Overall: Fundamentals do not support an impatient “buy now” decision; the company is still in a loss-making phase with no revenue showing in this snapshot.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data provided.
Wall Street pro view (inferred from available data):
- Pros: If a catalyst emerges, high IV and small-float dynamics can drive sharp upside moves.
- Cons: Lack of revenue visibility in the snapshot and worsening losses/EPS make it hard to justify buying without a clear technical breakout or catalyst.
Politician/influential trading: No recent congress trading data available; hedge fund and insider trends are reported as neutral.

Analyst Rating

Wall Street analysts forecast GRCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRCE is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 3.480

Low

Averages

High

Current: 3.480

Low

Averages

High

HC Wainwright & Co.

Oren Livnat

Strong Buy

Reiterates

$12

AI Analysis

2025-02-18

Reason

HC Wainwright & Co.

Oren Livnat

Price Target

$12

AI Analysis

2025-02-18

Reiterates

Strong Buy

Reason

GRCE Should I Buy

GRCE Should I Buy

Should You Buy Grace Therapeutics, Inc (GRCE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch